Company
CytoDyn Inc.
Public · CYDYUnited States
CytoDyn Inc. is a publicly traded clinical-stage biotechnology company developing leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor. The company is primarily focused on applying leronlimab to treat solid-tumor cancers, with additional exploration of its potential in inflammatory diseases. The CCR5 receptor is implicated in tumor metastasis, infection, and immune signaling.
CytoDyn Inc. is a publicly traded company, based in the United States. It trades under the ticker CYDY. Leadership tracked by CEOInsider includes Robert E. Hoffman (CEO).
Leadership
Current